The First Affiliated Hospital of Soochow University: Lymphoma, Large B-Cell, Diffuse trials

The registry lists 10 Lymphoma, Large B-Cell, Diffuse studies with The First Affiliated Hospital of Soochow University as lead sponsor. 8 are open to participants now and 0 have results posted.

Phase 2 8No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell LymphomaNot yet recruitingNCT07774234Phase 2
• A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaNot yet recruitingNCT07599423Phase 2
• Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 MutationRecruitingNCT07499271Phase 2
• Pomalidomide, Rituximab and Orelabrutinib Combined With Polatuzumab Vedotin in the Treatment of Newly Diagnosed Elderly Patients With DLBCLRecruitingNCT07072208Not applicable
• Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCLRecruitingNCT06682130Phase 2
• Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL PatientsRecruitingNCT05823701Phase 2
• Pro-miniCHOP-like Regimen for Treatment-naive Elderly PatientsRecruitingNCT05809180Not applicable
• Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCLRecruitingNCT04835870Phase 2
• Efficacy and Safety of Sequential Autologous Hematopoietic Stem Cell Transplantation Combined With Tafasitamab, Lenalidomide, and Standard Immunochemotherapy for Relapsed/Refractory Diffuse Large B-cell LymphomaActive, not recruitingNCT07621406Phase 2
• Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCLStatus unknownNCT05498259Phase 2